GlassScriptPhysician profile
Darren Matthew Chapman
NPI 1184831893
$845.57
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $85.00 · 2021: $274 · 2022: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $345.83 | 2019-2022 | |
| Antares Pharma, INC. | $204.52 | 2019-2022 | |
| Boston Scientific Corporation | $69.63 | 2019 | |
| 180 Medical, INC. | $56.99 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $40.16 | 2019 | |
| Allergan, INC. | $30.82 | 2019 | |
| Abbvie INC. | $27.75 | 2021 | |
| Merck Sharp & Dohme LLC | $22.47 | 2021 | |
| Clarus Therapeutics INC. | $17.82 | 2021 | |
| Baudax Bio INC. | $16.00 | 2021 | |
| Mission Pharmacal Company | $13.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.